Ultime notizie per Disco (OTC:DSCSY) Azioni

Disco Corp is a Japan-based company that manufactures and distributes precision processing and other manufacturing equipment. The firm's product portfolio includes dicing saws, laser saws, grinders, polishers, wafer mounters, die separators, surface planers, water jet saws, dicing blades, grinding wheels, polishing wheels, and related products. Precision processing equipment, predominantly grinders and dicers, make up roughly half of the firm's sales. The firm generates more than half of its revenue in Asia, with the rest coming from Japan, Europe, and the Americas.

Disco Corp

WIIM

IT Tech Packaging shares are trading lower after the company announced a $1.4 million public offering.

AFMD

Trading Halt: Halt status updated at 8:50:00 AM ET: Quotation Resumption: News and Resumption Times

BMO Capital analyst Edward DeArias initiates coverage on Black Hills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKH#NYSE">BKH</a>) with a Outperform rating and announces Price Target of $68.

News

Price Target

Initiation

Analyst Ratings

BMO Capital Initiates Coverage On Black Hills with Outperform Rating, Announces Price Target of $68

D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) with a Buy and maintains $25 price target.

HUMA

D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target

Affirmed N.V. shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target from $5 to $0.39.

OMS Energy Technologies Inc. ("OMS" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMSE#NASDAQ">OMSE</a>), a growth-oriented manufacturer of surface wellhead systems and oil country tubular goods for the oil and gas industry, today announced the pricing of its initial public offering (the "Offering") of 3,703,704 ordinary shares, par value US$0.0001 per share (the "Ordinary Shares"), at a public offering price of US$9.00 per share, for a total base offering size of US$33.3 million, assuming the underwriters do not exercise their option to purchase additional ordinary shares, before deducting underwriting discounts and other related expenses.
The Ordinary Shares are expected to begin trading on the Nasdaq Capital Market (the "NASDAQ") on May 13 2025, under the ticker symbol "OMSE." The offering is expected to close on May 14, 2025, subject to customary closing conditions.
In addition, OMS has granted the underwriter a 45-day option from the date of the final prospectus to purchase up to 555,555 additional ordinary shares at the public offering price, less underwriting discounts and commissions.

IPOs

OMSE

OMS Energy Technologies Prices $33.3M IPO at $9/Shr, Offering 3.7M Ordinary Shares

Promising results from the first-in-human study demonstrated that, at three-years post implantation, VenoValve remained safe and effective--achieving a high rate of patency, restoring deep venous competence and maintaining clinical benefits
Company has submitted PMA application for the VenoValve to the U.S. Food and Drug Administration (FDA) with a decision anticipated in the second half of 2025
IRVINE, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / May 13, 2025 / enVVeno Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that its manuscript titled, "<a href="https://pr.report/acgk">Three-Year Outcomes of Surgical Implantation of a Novel Bioprosthetic Valve for the Treatment of Deep Venous Reflux</a>1," has been published in the in the peer-reviewed journal, Annals of Vascular Surgery.
The VenoValve was surgically implanted in the femoral vein of eleven subjects with active or healed venous ulcers (CEAP classifications C5-C6). Eight subjects completed three years of follow-up, with key findings including:
Primary patency: 79% (Kaplan-Meier curve) at three years
Symptom relief: 7 point improvement Venous Clinical Severity Score; 84% reduction in pain on the Visual Analog Scale (VAS)
The VenoValve remained safe and effective, achieving target patency and maintaining competence and clinical benefits
The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025.

Biotech

General

NVNO

enVVeno Medical Announces That Its Manuscript Titled, "Three-year Outcomes Of Surgical Implantation Of A Novel Bioprosthetic Valve For The Treatment Of Deep Venous Reflux" Has Been Published In The In The Peer-Reviewed Journal, Annals Of Vascular Surgery

Consumer prices in the U.S. eased faster than expected in April, with fresh tariffs introduced by President Donald Trump appearing not to have a swift and tangible impact on the cost of living. 
The Consumer Price Index (CPI) was 2.3% higher compared to a year ago, the Bureau of Labor Statistics said Tuesday, missing economists' expectations of 2.4% and the previous reading. 
The monthly gain was 0.2%, rebounding from a prior decline of 0.1%, yet falling short of a 0.3% forecasted.
The core CPI, which strips out volatile food and energy categories, rose to 2.8% on an annual basis, unchanged from both the previous and expected 2.8%. Month over month, it increased 0.2%, inching higher from the 0.1% uptick in March but below expectations of 0.3%
Shelter costs rose 0.3% in April, contributing to over half of the total monthly increase in the overall consumer price index.
Airline fares, used vehicles, communication services and apparel were among the key categories that saw price declines in April.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Metric</th>
<th>April 2025</th>
<th>March 2025</th>
<th>Forecast</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headline CPI (YoY)</td>
<td>2.3%</td>
<td>2.4%</td>
<td>2.4%</td>
</tr>
<tr>
<td>Headline CPI (MoM)</td>
<td>0.2%</td>
<td>-0.1%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Core CPI (YoY)</td>
<td>2.8%</td>
<td>2.8%</td>
<td>2.8%</td>
</tr>
<tr>
<td>Core CPI (MoM)</td>
<td>0.2%</td>
<td>0.1%</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">What Does This Mean For The Fed?</h3>
Before the release, interest rate futures reflected slim odds of policy easing. CME FedWatch data showed just an 8% chance of a rate cut in June, and 36% in July. 
Markets priced in only 60 basis points—0.6 percentage points—of total cuts by the end of 2025, well below earlier expectations for more aggressive easing.
Yet the modest progress is unlikely to sway the Federal Reserve toward near-term rate cuts, as markets remain cautious amid persistent inflation risks.
Inflation remains above the central bank's 2% target, and with shelter and services inflation proving sticky, policymakers may choose to keep borrowing costs elevated through the second half of the year.
<h3 class="wp-block-heading">Market Reactions: Dollar And Yields Ease Slightly</h3>
The U.S. Dollar Index (DXY) – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) slightly eased 0.1%, down following Monday's sharp 1.3% rally. The 2-year Treasury yield edged down to 3.98%. 
U.S. stock futures, which had rallied on Monday after news of a U.S.-China tariff truce, were mixed in premarket trading as traders recalibrated inflation and interest rate expectations.
Futures on the S&amp;P 500 index were up 0.2%, while contracts on the Dow Jones Industrial Average fell 0.4%. 
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45368550/apple-may-up-its-numbers-amid-china-tariff-truce-trump-talks-500-billion-us-investment-after-tim-cook-call">Apple May &#8216;Up Its Numbers&#8217; Amid China Tariff Truce: Trump Talks $500 Billion US Investment After Tim Cook Call</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Macro Economic Events

Econ #s

Economics

PowerShares DB US Dollar Index Bullish Fund

Inflation Eases In April As Trump's Tariffs Don't Push Prices Higher

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Barclays analyst Julian Mitchell upgraded the rating for Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) from Equal-Weight to Overweight and raised the price target from $69 to $90. Stanley Black &amp; Decker shares closed at $72.53 on Monday. <a href="https://www.benzinga.com/quote/swk/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Manav Gupta upgraded PBF Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>) from Neutral to Buy and boosted the price target from $20 to $26. PBF Energy shares closed at $20.79 on Monday. <a href="https://www.benzinga.com/quote/pbf/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Mircea Dobre upgraded Terex Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) from Neutral to Outperform and raised the price target from $48 to $66. Terex shares closed at $44.79 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Mircea Dobre upgraded the rating for Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) from Neutral to Outperform and boosted the price target from $309 to $395. Caterpillar shares closed at $342.55 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Joel Beatty upgraded argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) from Neutral to Outperform and maintained the price target of $680. argenx shares closed at $560.90 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CAT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="565" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13084658/image-143-1024x565.png" alt="" class="wp-image-913435" style="width:600px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13084658/image-143-1024x565.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13084658/image-143-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13084658/image-143-768x424.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13084658/image-143.png 1137w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Markets

Trading Ideas

ARGX

NXRT

This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Offers a Significant Premium of 61% to TrueBlue Stockholders
HireQuest's High-Margin Franchising Model to drive near-term profitability and enhanced value for shareholders

HireQuest Proposes Acquisition Of Trueblue For $7.50/Share

HCWB

HCW Biologics shares are trading higher after the company announced it presented studies on HCW9206.

Savers Value Village, Inc. (the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>), the largest for-profit thrift operator in the United States ("U.S.") and Canada for value priced pre-owned clothing, accessories and household goods, today announced the commencement of a proposed secondary public offering (the "Offering") of 15,000,000 shares of its common stock offered by certain funds, investment vehicles or accounts managed or advised by Ares Management LLC or its affiliates (the "Ares Selling Stockholders") and the chief executive officer of the Company (the "Management Selling Stockholder" and, together with the Ares Selling Stockholders, the "Selling Stockholders"). As part of the Offering, the Ares Selling Stockholders also intend to grant the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of common stock at the public offering price, less the underwriting discount.
In addition, the Company has authorized the concurrent purchase from the underwriters of $20.0 million of the shares of common stock as part of the Offering, at a price per share equal to the price per share to be paid by the underwriters to the Selling Stockholders (the "Concurrent Share Repurchase"). The Company intends to fund the Concurrent Share Repurchase from its existing cash on hand and it is not part of its existing share repurchase program authorized on November 9, 2023. The underwriters will not receive any compensation for the shares being repurchased by the Company.

Offerings

Buybacks

Savers Value Village Announces 15M Share Secondary Offering By Ares And CEO, And $20M Concurrent Share Repurchase Funded By Cash On Hand

Hannover Rueck (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HVRRY#OTC">HVRRY</a>) reported quarterly earnings of $2.09 per share. This is a 16.73 percent decrease over earnings of $2.51 per share from the same period last year. The company reported $7.33 billion in sales this quarter. This is a 1.13 percent increase over sales of $7.25 billion the same period last year.

Earnings

Hannover Ruckversicherungs Registered shares 

HVRRY

Hannover Rueck Q1 EPS $2.09 Down From $2.51 YoY, Sales $7.33B Up From $7.25B YoY

LOBO

LOBO EV Technologies shares are trading higher after the company issued a year-over-year increase in its FY25 revenue guidance.

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) from Neutral to Neutral.

Reiteration

AGEN

HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral

- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model -
- The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) -
- Findings highlight BMB-101's potential to address critical gaps in SUDEP prevention -
NEW YORK and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#CSE">DRUG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) ("Bright Minds" or the "Company"), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced positive findings from its DBA/2 mouse model study. BMB-101, the Company's novel scaffold 5-HT2C Gq-protein biased agonist, demonstrated a complete elimination of drop attacks in the DBA/2 mouse model.

CSE:DRUG

DRUG

Bright Minds Biosciences Announces Findings From Its DBA/2 Mouse Model Study Evaluating BMB-101; Demonstrated A Complete Elimination Of Drop Attacks; Findings Highlight BMB-101's Potential To Address Critical Gaps In SUDEP Prevention

ARCT

Arcturus Therapeutics shares are trading higher after the company reported Q1 financial results and beat its EPS and revenue estimates.

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/05/12/final-trades-citigroup-truist-financial-and-amazon.html">Halftime Report Final Trades</a>,&#8221; Jim Lebenthal of Cerity Partners named Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), a <a href="https://www.benzinga.com/quote/C/analyst-ratings">financial stock, as his final trade.</a>
Supporting his view, Oppenheimer analyst Chris Kotowski, on April 28, maintained Citigroup with an Outperform rating and raised the price target from $91 to $94.
Stephanie Link, chief investment strategist and portfolio manager at Hightower, said Truist Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) has a 5% dividend yield.
Lending support to her choice, Truist Finl, on April 17, reported quarterly earnings of 87 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $4.947 billion which beat the analyst consensus estimate of $4.937 billion.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Joseph M. Terranova, Senior Managing Director for Virtus Investment Partners, picked Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) as his final trade.
Shares of Amazon.com rose sharply on Monday after the U.S. and China announced a temporary easing of tariffs, marking a significant step toward de-escalating long-standing trade tensions. The move lifted investor sentiment across sectors and boosted shares of companies heavily reliant on global supply chains.
Price Action:
<ul class="wp-block-list">
<li>Citi shares gained 4.8% to close at $74.91 on Monday.</li>
<li>Truist Financial shares rose 5.4% to settle at $41.12 during Monday's session.</li>
<li>Amazon shares jumped 8.1% to close at $208.64 on Monday.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/05/45347009/top-2-tech-stocks-that-may-crash-in-q2">Top 2 Tech Stocks That May Crash In Q2</a></li>
</ul>
Image: Shutterstock

Analyst Color

AMZN

Citigroup, Truist Financial And A Consumer Cyclical Stock On CNBC's 'Final Trades'

Barrington Research analyst Vincent Colicchio maintains Climb Global Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMB#NASDAQ">CLMB</a>) with a Outperform and maintains $136 price target.

CLMB

Barrington Research Maintains Outperform on Climb Global Solutions, Maintains $136 Price Target

RGNX

Regenxbio shares are trading higher following Q1 financial results and after the company announced FDA acceptance and priority review of BLA for RGX-121.

Comments

Disco

Notizie

Ultime notizie per Disco (OTC:DSCSY) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO